Adverse effects: 2. Extrapyramidal ‐ akathisia · patients with schizophrenia
ORAL FLUPHENAZINE probably leads to higher adverse effects: Extrapyramidal effects (akathisia) ‐ short… compared with PLACEBO (moderate certainty).
1 finding from 1 review
Adverse effects: extrapyramidal adverse effectsParkinsonism (rigidity) short term (< 3 months) Clinical diagnoses · patients with schizophrenia
ORAL FLUPHENAZINE probably leads to higher adverse effects: Extrapyramidal effects (rigidity) ‐ short… compared with PLACEBO (moderate certainty).
1 finding from 1 review
Mental state · patients with schizophrenia
1 finding from 1 review
Adverse effect: extrapyramidal symptoms ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early ‐ short term ‐ due to lack of efficacy · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE (ORAL) changes leaving the study early ‐ inefficacy short term (up to 12 weeks) compared with RISPERIDONE (very low certainty).
1 finding from 1 review
Clinically important response (defined by study) ‐ short term (up to 12 weeks) decreased rate of BPRS score < 20% · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE (ORAL) changes clinically important response (defined by study) ‐ short term (up to… compared with QUETIAPINE (very low certainty).
1 finding from 1 review
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early ‐ short term ‐ due to lack of efficacy · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE (ORAL) changes leaving the study early ‐ inefficacy ‐ short term (up to 12 weeks) compared with QUETIAPINE (very low certainty).
1 finding from 1 review
Clinically important response (defined by study) ‐ short term (up to 12 weeks) decreased rate of PANSS score < 40%, decreased rate of BPRS score < 40% · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE (ORAL) changes clinically important response (defined by study) ‐ short term (up to… compared with OLANZAPINE (very low certainty).
1 finding from 1 review
Adverse effects: 2. Extrapyramidal ‐ akathisia · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE (ORAL) changes adverse effects: Extrapyramidal effects ‐ akathisia ‐ short term (up… compared with OLANZAPINE (very low certainty).
1 finding from 1 review
Leaving the study early ‐ short term ‐ due to lack of efficacy · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE (ORAL) changes leaving the study early: inefficacy ‐ short term (up to 12 weeks) compared with OLANZAPINE (very low certainty).
1 finding from 1 review
Adverse effects: Extrapyramidal effects ‐ concomitant anticholinergic medication ‐ short term (up to 12 weeks) Participants requiring concomitant anticholinergic medication · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE (ORAL) changes adverse effects: Extrapyramidal effects ‐ concomitant… compared with AMISULPRIDE (very low certainty).
1 finding from 1 review
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE (ORAL) changes leaving the study early ‐ any reason ‐ short term (up to 12 weeks) compared with AMISULPRIDE (very low certainty).
1 finding from 1 review
Clinically important response (defined by study) ‐ short term (up to 12 weeks) decreased rate of BPRS score < 20% · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE (ORAL) changes clinically important response (defined by study) ‐ short term (up to… compared with RISPERIDONE (very low certainty).
1 finding from 1 review